JUN 2 3 2009

PTO/SB/08 (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid

Under the Paperwork Reduction Act of 1990 persons a

Substitute for form 1449/PTO **INFORMATION DISCLOSURE** STATEMENT BY APPRLICANT.

Date Submitted: JUN 23 2009

(use as many sheets as necessary)

Sheet of 2

Complete if Known					
Application Number	10/567,328				
Filing Date	8/6/2004	_			
First Named Inventor	Makoto SAWADA	_			
Art Unit	1649	_			
Examiner Name	Kimberly BALLARD	_			
Attorney Docket Number	084335-0201	_			

U.S. PATENT DOCUMENTS					
Examin	Cite	Document Number	Publication Date	Nome of Batasia	Pages, Columns, Lines,
er Initials*	No. <sup>1</sup>	Number-Kind Code <sup>2</sup> (if known)	le <sup>2</sup> (if MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
					- Iguioo i ppoui

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4-</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т6
	F1	WO 03/009881 A2	02/06/2003	Imarx Therapeutics, Inc.	i garda rippodi	一
	F2_	WO 03/020751 A2	03/13/2003	King's College London		
						t

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	F3	Supplementary European Search Report mailed April 8, 2009, in European Patent Application EP 06783020), 4 pages.	
	F4	BODER et al., "Yeast surface display for screening combinatorial polypeptide libraries," Nature Biotechnology, June 1, 1997, 15:553-557.	
	F5	EGLETON et al., "Transport of Opioid Peptides into the Central Nervous System," Journal of Pharmaceutical Sciences, November 1998, 87(11):1433-1439.	
	F6	KIM et al., "Human neural stem cells genetically modified for brain repair in neurological disorders," Neuropathology: Official Journal of the Japanese Society of Neuropathology, September 2004, 24(3):159-171.	
	F7	KONDO et al., "Yeast cell-surface display-applications of molecular display," Applied Microbiology and Biotechnology, March 1, 2004, 64(1):28-40.	
	F8	LAAKKONEN et al., "A tumor-homing peptide with a targeting specificity related to lymphatic vessels," Nature Medicine, June 10, 2002, 8(7):751-755.	
	F9	LAAKKONEN et al., "Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells," Proc. Natl. Acad. Sci., June 22, 2004, 101(25):9381-9386.	

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for for	rm 1449	P/PTO	Complete if Known		
	INFORMATION I	DISCL	OSURE	Application Number	10/567,328	
	STATEMENT BY	APPL	LICANT	Filing Date	8/6/2004	
Da	te Submitted: ၂၂၂	N 23	2009	First Named Inventor	Makoto SAWADA	
Date Submitted. Out 2 0 2000				Art Unit	1649	
(use as many sheets as necessary)				Examiner Name	Kimberly BALLARD	
Sheet	2	of	2	Attorney Docket Number	084335-0201	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	F10	MAKAR et al., "Brain-derived neurotrophic factor (BDNF) gene delivery into the CNS using bone marrow cells as vehicles in mice," Neuroscience Letters, February 17, 2004, 356:215-219.				
	F11	PIWKO et al., "Localization and Pharmacological Characterization of Somatostatin Recognition Sites in the Human Cerebellum," Neuropharmacology, June 1996, 35(6):713-723.				

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.